Drug Profile
Research programme: neurological disorders therapies - Vyrex/Immune Response
Latest Information Update: 03 Jul 2006
Price :
$50
*
At a glance
- Originator Immune Response Corporation; Vyrex Corporation
- Class
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS trauma; Spinal cord injuries
Most Recent Events
- 01 Aug 2003 Discontinued - Preclinical for CNS trauma in USA (unspecified route)
- 01 Aug 2003 Discontinued - Preclinical for Spinal cord injuries in USA (unspecified route)
- 30 Jun 1998 Preclinical trials in CNS trauma in USA (unspecified route)